Bhaskar Strivstava joins Triveni Bio as CMO

12 June 2024

US biotech Triveni Bio today announced that Dr Bhaskar Srivastava has joined the company as chief medical officer (CMO).

The company is pioneering a genetics-informed precision medicine approach to develop p treatments for immunological and inflammatory (I&I) disorders, and says that Dr Strivastava will play a critical role as Triveni advances its lead asset (TRIV-509) into the clinic in the first half of 2025 and brings second-generation combination approaches into the clinic in 2026.

“We are thrilled to welcome Bhaskar to the team,” said Vishal Patel, chief executive of Triveni Bio. “He arrives at a key moment for the company, equipped with an impressive track record of leading dermatology strategy and clinical programs. Bhaskar’s extensive training as a dermatologist and immunologist will further our goal of bringing innovation for I&I diseases,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK